Here are relevant reports on : viral-vector-manufacturing-market
-
Viral Vector & Plasmid DNA Manufacturing Market by Type (Viral Vector (Retroviruses, Adenoviruses, AAV, Lentiviruses), Plasmid DNA), Workflow (Upstream, Downstream), Application (Cell & Gene Therapy), Diseases (Cancer), End User - Global Forecast to 2028
The global viral vector manufacturing market, valued at US$4.8 billion in 2022, stood at US$5.5 billion in 2023 and is projected to advance at a resilient CAGR of 18.2% from 2023 to 2028, culminating in a forecasted valuation of US$12.8 billion by the end of the period. The growth of this market is majorly driven by g rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, and effectiveness of viral vectors in gene therapy delivery.
- Published: June 2023
- Price: $ 4950
- TOC Available:
-
Vector Database Market By Vector Database Solution (Vector Generation & Indexing, Vector Search & Query Processing, Vector Storage & Retrieval), AI Language Processing, Computer Vision, Recommendation Systems - Global Forecast to 2030
The vector database market is expected to grow from USD 2,652.1 million in 2025 to USD 8,945.7 million by 2030, at a compound annual growth rate (CAGR) of 27.5% during the forecast period. The Key Players Microsoft (US), Elastic (US), MongoDB (US), Google (US), AWS (US), Redis (US), Alibaba Cloud(US), DataStax (US), SingleStore (US), Pinecone (US), Zilliz (US), KX (US), Marqo.ai (US), ActiveLoop (US), Supabase (US), Jina AI (Germany), Typesense (US), Weaviate (Netherlands), GSI Technology (US), Kinetica (US), Qdrant (Germany), ClickHouse (US), OpenSearch (US), Vespa.ai (Norway), and LanceDB (US).
- Published: December 2025
- Price: $ 4950
- TOC Available:
-
Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR, RSV), Route of Administration (IM, SC, Oral)-Global Forecast to 2030
The global vaccines market, valued at US$59.52 billion in 2024, stood at US$50.46 billion in 2025 and is projected to advance at a resilient CAGR of 4.8% from 2025 to 2030, culminating in a forecasted valuation of US$63.66 billion by the end of the period.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
North America Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR), Route of Administration (IM, SC, Oral)- Global Forecast to 2030
The North America vaccines market, valued at US$25.95 billion in 2024, stood at US$25.29 billion in 2025 and is projected to advance at a resilient CAGR of 7.1% from 2025 to 2030, culminating in a forecasted valuation of US$35.68 billion by the end of the period. The vaccines market is growing rapidly, driven by swift global vaccine development and commercialization, higher rates of infectious diseases necessitating preventive vaccines, expanded immunization initiatives, innovations in vaccine technology, and increased government funding and investments for novel vaccines against diverse diseases.
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Asia Pacific Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR), Route of Administration (IM, SC, Oral) - Forecast to 2030
The Asia Pacific Vaccines market, valued at USD 9.46 billion in 2024, stood at USD 9.89 billion in 2025 and is projected to advance at a resilient CAGR of 9.0% from 2025 to 2030, culminating in a forecasted valuation of USD14.57 billion by the end of the period. The market is expanding quickly, driven by a rise in vaccine development and commercialization, heightened infectious disease rates, and the extensive use of preventive vaccines.
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Europe Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR, RSV), Route of Administration (IM, SC, Oral) - Forecast to 2030
The Europe vaccines market, valued at US$10.53 billion in 2024, stood at US$9.97 billion in 2025 and is projected to advance at a resilient CAGR of 6.6% from 2025 to 2030, culminating in a forecasted valuation of US$13.74 billion by the end of the period. The vaccines market is growing due to fast global developments and the commercialization of vaccines, rising rates of infectious diseases, which require preventive measures, and government initiatives to encourage vaccinations, immunization programs, advancements, and investments in new vaccines against various diseases.
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Vector Control Market by Technology (Chemical, Physical & Mechanical, Biological), Control Method (Comprehensive, Integrated Vector Management, Targeted), Vector Type, End-Use Sector, Mode of Application and Region - Global Forecast to 2029
The market for vector control is projected to reach USD 29.80 billion by 2029, at a CAGR of 6.5% during the forecast period. The report profiles key players such as BASF SE (Germany), Rentokil Initial Plc (UK), Sumitomo Chemical Co., Ltd. (Japan), Syngenta Group (Switzerland), FMC Corporation (US), Ecolab (US), Rollins Inc. (US), Anticimex (Sweden), UPL (India), Neogen Corporation (US), Senestech, Inc. (US), Environmental Science U.S. Inc. (US), Bell Laboratories Inc. (US), Pelgar International (UK), S. C. Johnson & Son, Inc. (US).
- Published: November 2024
- Price: $ 4950
- TOC Available:
-
Cell & Gene Therapy Manufacturing Services Market Size, Share & Trends by Type (Allogeneic, Autologous, Viral Vector, Non-viral vector), Indication (Oncology, Orthopedic, Ophthalmology), Application (Clinical, Commercial), End User (Pharma, Biotech) - Global Forecast to 2027
The size of global cell & gene therapy manufacturing services market in terms of revenue was estimated to be worth $5.1 billion in 2022 and is poised to reach $11.5 billion by 2027, growing at a CAGR of 17.5% from 2022 to 2027. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.
- Published: January 2023
- Price: $ 4950
- TOC Available:
-
Viral Clearance Market by Application (Recombinant Proteins, Blood, Vaccines), End User (Pharmaceutical & Biotechnology Companies, CROs), Method (Viral Removal (Chromatography, Nanofiltration), Viral Inactivation (Low pH)) - Global Forecasts to 2023
The global viral clearance market is projected to reach USD 724.5 million by 2023, growing at a CAGR of 21.7%. The key players in the global viral clearance market are Wuxi Biologics (Cayman) (China), Merck KGaA (Germany), Charles River Laboratories International Inc. (US), and Texcell Inc. (France), Kedrion (Italy), Vironova Biosafety (Sweden), Clean Cells (France), BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany), and ViruSure GmbH (Austria).
- Published: September 2018
- Price: $ 4950
- TOC Available:
-
Depth Filtration Market by Media Type (Cellulose, Activated Carbon), Product (Capsule, Sheet, Module), Application (Final Product Processing (Biologics), Cell Clarification, Viral Clearance, Operation Scale (Manufacturing, Lab) - Global Forecasts to 2024
The global depth filtration market growth is primed to transition from $1.7 billion in 2019 to $2.9 billion by 2024, showcasing a strong CAGR of 9.0%. The growth of this market is majorly driven by factors such as the growing adoption of disposable filters and benefits such as ease of use and low cost of media and filters.
- Published: April 2020
- Price: $ 4950
- TOC Available:
Records 1 to 10 of 50
